| Investigator, Principal |
ICVP, NCT04634383: A Phase I Feasibility Study of an Intracortical Visual Prosthesis () for People With Blindness |
|
|
| Recruiting | 1 | 5 | US | WFMA - wireless floating microelectrode array, ICVP System, ICVP, Intracortical Visual Prosthesis | Illinois Institute of Technology, National Institute of Neurological Disorders and Stroke (NINDS), Rush University Medical Center, The Chicago Lighthouse, The University of Texas at Dallas, University of Chicago, Johns Hopkins University | Ocular Injury, Optic Nerve Diseases, Photoreceptor Degeneration, Blindness,Acquired | 08/23 | 08/23 | | |
NCT05394675: A Study of DS-9606a in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 125 | Europe, US | DS-9606a | Daiichi Sankyo | Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Germ Cell Tumor | 02/26 | 02/26 | | |
ZIRDOSE-CP, NCT05861778: Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma |
|
|
| Completed | 1 | 10 | RoW | 89Zr-Girentuximab, 89Zr-DFO-girentuximab, 89Zr-TLX250, TLX250CDx | Telix International Pty Ltd, Grand Pharmaceutical (China) Co., Ltd. | Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer | 11/23 | 11/23 | | |
KEYNOTE-797, NCT04042701: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 115 | Europe, US | Trastuzumab deruxtecan (DS-8201a), Pembrolizumab | Daiichi Sankyo, AstraZeneca UK Limited, Merck Sharp & Dohme LLC | Breast Cancer, Non-small Cell Lung Carcinoma | 12/24 | 08/25 | | |
NCT04894110: Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema |
|
|
| Active, not recruiting | 1 | 42 | US | EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose | Emmecell | Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation | 10/24 | 10/24 | | |
KEYNOTE-B43, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) |
|
|
| Active, not recruiting | 1 | 145 | Europe, Japan, US, RoW | Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, Pembrolizumab, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Advanced or Metastatic NSCLC | 06/25 | 06/25 | | |
|
|
| Recruiting | 1 | 210 | Japan, US | Valemetostat tosylate, DS-3201b, T-DXd, DS-8201a, ENHERTU, Dato-DXd, DS-1062a | Daiichi Sankyo | Advanced Solid Tumor | 11/28 | 11/28 | | |
NCT05755191: A Study to Assess NEU-411 in Healthy Participants |
|
|
| Completed | 1 | 147 | RoW | NEU-411, Placebo | Neuron23 Inc. | Healthy | 06/24 | 06/24 | | |
NCT05628961: Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics |
|
|
| Recruiting | 1 | 42 | US | HOPO 14-1 | SRI International | Toxicity;Chemical | 04/24 | 04/24 | | |
NCT04528836: First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 130 | US | BBP-398 (Formerly known as IACS-15509) | Navire Pharma Inc., a BridgeBio company | Tumor, Solid | 05/24 | 02/25 | | |
NCT05940571: First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors |
|
|
| Recruiting | 1 | 41 | Europe | MBF-362 | Medibiofarma S.L. | Cancer | 10/24 | 11/24 | | |
| Recruiting | 1 | 56 | US | THB335 single dose, Single dose placebo, THB335 fasted/fed, Placebo fasted/fed, THB335 multiple dose, Multiple dose placebo | Third Harmonic Bio, Inc. | Healthy | 03/25 | 03/25 | | |
NCT04707248: A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors |
|
|
| Recruiting | 1 | 180 | Japan, US | DS-6000a, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Renal Cell Carcinoma, Ovarian Tumor | 11/24 | 11/24 | | |
NCT04953910: Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment |
|
|
| Recruiting | 1 | 27 | Europe | ASTX727, Oral decitabine and cedazuridine | Astex Pharmaceuticals, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 12/24 | 12/24 | | |
NCT05868174: Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | 89Zr-TLX250, 89Zr-DFO-girentuximab, 177Lu-TLX250 and Peposertib, 177Lu-DOTA-girentuximab | Telix Pharmaceuticals (Innovations) Pty Limited, Merck KGaA, Darmstadt, Germany | Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma | 12/24 | 12/26 | | |
NCT04953897: Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment |
|
|
| Recruiting | 1 | 18 | Europe | ASTX727, Oral decitabine and cedazuridine | Astex Pharmaceuticals, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 12/24 | 12/24 | | |
NCT05029960: Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas |
|
|
| Recruiting | 1 | 30 | US | Brivaracetam | University of Rochester | Brain Tumor | 12/24 | 12/24 | | |
| Recruiting | 1 | 890 | Japan, US | Datopotamab Deruxtecan (Dato-DXd), DS1062a, Study treatment, Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash | Daiichi Sankyo Co., Ltd., Daiichi Sankyo, Inc., AstraZeneca | Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer | 01/25 | 01/25 | | |
|
|
|
NCT05859724: Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD) |
|
|
| Recruiting | 1 | 140 | Europe, Canada, US | NM26-2198, Placebo | Numab Therapeutics AG, Kaken Pharmaceutical Co., Ltd. | Atopic Dermatitis | 02/25 | 04/25 | | |
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 280 | Japan, US, RoW | HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 06/25 | 02/26 | | |
| Recruiting | 1 | 12 | Europe, RoW | 131I-IPA, 18F-FET | Telix International Pty Ltd | Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme | 06/25 | 06/25 | | |
NCT05765851: A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 78 | Europe, Canada, US | DS-1103a, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Advanced Solid Tumor, Breast Cancer | 06/26 | 06/26 | | |
NCT06279728: Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients |
|
|
| Available | N/A | | Europe, US | Datopotamab deruxtecan, Dato-DXd, DS-1062a | Daiichi Sankyo, AstraZeneca | Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer | | | | |
NCT04886544: Clinical Study to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 720 Injected for Jawline Contouring |
|
|
| Completed | N/A | 72 | Europe | YVOIRE Y-Solution 720 | LG Chem | Jaw Volume Deficit | 05/22 | 01/23 | | |
| Completed | N/A | 10 | US | Transcranial Magnetic Stimulation device, TMS | University of Colorado, Denver | Visual Snow Syndrome | 11/22 | 11/22 | | |
NCT05133973: Feasibility Study of a Transdermal Continuous Glucose Monitoring (CGM) System in Diabetic Patients |
|
|
| Recruiting | N/A | 12 | Europe | FiberSense CGM | EyeSense GmbH | Diabetes | 12/22 | 12/22 | | |
PAROS, NCT04745520: Randomized Clinical Trial of Rib Fixation Versus Medical Analgesia in Uncomplicated Rib Fractures on Pain Control. |
|
|
| Recruiting | N/A | 102 | Europe | Rib fixation, Analgesia | Benoît Bédat, Centre Hospitalier Universitaire Vaudois, Hôpital du Valais | Rib Fractures | 03/23 | 03/24 | | |
| Recruiting | N/A | 950000 | US, RoW | There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery. | NICHD Global Network for Women's and Children's Health | Pregnancy Outcome Trends in Low-resource Geographic Areas | 01/25 | 01/25 | | |
NCT04445207: Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19 |
|
|
| No Longer Available | N/A | | US | Convalescent Plasma | Jonathan Gerber | COVID, Sars-CoV2, Corona Virus Infection | | | | |
NCT03929731: Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV) |
|
|
| Recruiting | N/A | 72 | RoW | Indocyanine Green Angiography, Optical Coherence Tomography-Angiography, Fundus photography, Fundus fluorescein, Optical Coherence Tomography | Singapore National Eye Centre | Polypoidal Choroidal Vasculopathy | 06/25 | 06/25 | | |
NCT05769751: A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer |
|
|
| Completed | N/A | 865 | RoW | Electronic medical record and hospital information system or other available resources | Daiichi Sankyo, Inc. | HER2-positive Breast Cancer | 07/23 | 07/23 | | |
BIOPATTERN, NCT06259019: Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease |
|
|
| Recruiting | N/A | 300 | Europe | Liquid Biopsy System (LBS), LBS | PlaqueTec Ltd, Royal Papworth Hospital | Coronary Artery Disease | 05/25 | 07/25 | | |
| Completed | N/A | 63 | US | Healthy Child Development Program | University of South Carolina | Child Behavior, Child Health, Child, Preschool, Parents | 01/24 | 01/24 | | |
| Active, not recruiting | N/A | 15886 | Canada, US | Limited Intraoperative Benzodiazepine, Liberal Intraoperative Benzodiazepine | Population Health Research Institute | Delirium, Post-cardiac Surgery | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 32 | RoW | | University of Sydney, Western Sydney Local Health District | Head and Neck Neoplasms, Radiation Therapy Complication | 12/24 | 12/24 | | |
EUROPA T-DXd, NCT05458401: EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan |
|
|
| Completed | N/A | 256 | Europe | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo | HER2-positive Breast Cancer | 12/23 | 12/23 | | |
OPBIM, NCT06353464: A Translational Understanding of Obesity-Related Phenotypes Using Brain Imaging and Manipulation |
|
|
| Recruiting | N/A | 80 | US | Ensure and Water | Drexel University | Obesity | 09/25 | 09/25 | | |
NCT06099639: Medical Access Program for Patritumab Deruxtecan |
|
|
| Available | N/A | | US | HER3-DXd, U3-1402 | Daiichi Sankyo | Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer | | | | |
HHiNPWT7DC, NCT05559697: Study Comparing iNPWT Dressing and Devices Affect on Bioburden Levels and Skin Condition After Seven Days |
|
|
| Completed | N/A | 16 | US | Sponsor incisional negative pressure wound therapy device and dressing, Standard of Care incisional negative pressure wound therapy system | DeRoyal Industries, Inc., Lincoln Memorial University | Skin Reaction to Mechanical, Thermal and Radiation Stimuli, Skin Sensitisation | 03/24 | 03/24 | | |
MEE, NCT04730700: Evaluation of Multi-Tined Expandable Electrode () Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management. |
|
|
| Recruiting | N/A | 50 | US | Radiofrequency Ablation with MEE, Conventional Medical Management | University of Kansas Medical Center | Chronic Low-back Pain | 11/23 | 11/23 | | |
NCT05120895: An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia |
|
|
| Active, not recruiting | N/A | 3300 | RoW | Mevalotin | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Dyslipidemia | 04/25 | 04/25 | | |
NCT05606094: Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia |
|
|
| Completed | N/A | 450 | RoW | | Daiichi Sankyo Co., Ltd. | Gastric Cancer | 11/23 | 11/23 | | |
NCT03866707: Epigenetic and Metabolomic Changes in Childhood Cancer Survivors |
|
|
| Terminated | N/A | 7 | US | One-time blood draw, Evaluation of CpG methylation, Metabolomic analysis | Wake Forest University Health Sciences | Childhood Cancer | 05/20 | 05/20 | | |
| Completed | N/A | 11 | US | Psychosocial intervention | Medical University of South Carolina | Aphasia, Stroke | 12/23 | 12/23 | | |
NCT06210776: A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) |
|
|
| Recruiting | N/A | 800 | RoW | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo | HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer | 03/28 | 03/28 | | |
NCT04910048: Impact of a POPOP on Preoperative Health, Eligibility, and Clinical & Patient-Reported Outcomes in TJA |
|
|
| Active, not recruiting | N/A | 46 | US | POPOP (preoperative patient optimization program), 20Lighter, SOC (standard of care) | University of Arkansas | Osteoarthritis, Knee, Osteoarthritis, Hip, Avascular Necrosis, Rheumatoid Arthritis | 04/23 | 12/24 | | |
NCT06204900: A Post-marketing Study to Evaluate a Novel Surgical Monitoring Technique Using the EARP Nerve Cuff in TLIF Surgery. |
|
|
| Not yet recruiting | N/A | 30 | US | Nerve Cuff and Retractor System | Retropsoas Technologies, LLC | Undergoing a Single-level or Two-level TLIF Surgery | 06/24 | 08/24 | | |
ACAB, NCT04292405: Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator |
|
|
| Recruiting | N/A | 60 | US | Wearable Cardioverter Defibrillator, AUDICOR AM | Zoll Medical Corporation | Heart Failure | 03/24 | 05/24 | | |
| Recruiting | N/A | 60 | US | BHmApp | William Beaumont Hospitals, University of Pennsylvania | Urinary Incontinence | 08/24 | 08/24 | | |
| Recruiting | N/A | 200 | Europe | | Chelsea and Westminster NHS Foundation Trust, ViiV Healthcare | HIV Infections, Gender Identity, Human Immunodeficiency Virus | 04/24 | 10/25 | | |
| Active, not recruiting | N/A | 70 | US | PQ Bypass System | Endologix | Peripheral Artery Diseases | 06/24 | 06/24 | | |
NCT03586414: MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women |
|
|
| Active, not recruiting | N/A | 31 | US | MITOQUINOL MESYLATE then placebo, MitoQ, Mitoquinol methanesulfonate, Placebo, then MITOQUINOL MESYLATE | University of Colorado, Denver, University of Colorado Nutrition Obesity Research Center (NORC) | Diastolic Dysfunction | 07/25 | 08/25 | | |
NCT06361797: Varying Bone Marrow-Derived Mesenchymal Stem Cells Concentrations' Impact on Rotator Cuff Repair Outcomes |
|
|
| Not yet recruiting | N/A | 150 | US | Rotator cuff repair augmented with whole bone marrow, Whole bone marrow, Bone marrow aspirate, Rotator cuff repair augmented with concentrated bone marrow, Bone marrow-derived mesenchymal stem cells, Bone marrow concentrate | Johns Hopkins University, ON Foundation | Rotator Cuff Tears | 07/26 | 12/27 | | |
NCT06340503: Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors |
|
|
| Recruiting | N/A | 20 | US | Research-grade accelerometer, National Comprehensive Cancer Network (NCCN) Education Materials, Garmin Vivofit activity tracker, Exercise Consultation Calls, Interview, Physical Activity Index Assessment (Intervention Arm), Physical Activity Index Assessment (Control Arm), Health Surveys | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Breast Cancer, Colon Cancer | 07/25 | 08/25 | | |
NCT02945085: 3D Team Care for Cognitively Vulnerable Older Adults |
|
|
| Recruiting | N/A | 576 | US | Home Based Care Team, Telephone Based Care Team | UConn Health, Patient-Centered Outcomes Research Institute, University of Connecticut | Dementia, Depression, Delirium | 07/24 | 07/24 | | |
NCT04931251: Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings |
|
|
| Recruiting | N/A | 780 | US | Financial Navigation | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Neoplasms, Carcinoma | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 80 | US | Gaming in a virtual environment | Yale University, National Heart, Lung, and Blood Institute (NHLBI) | Cardiovascular Diseases | 07/25 | 07/25 | | |
NCT04927052: A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment |
|
|
| Completed | N/A | 136 | Canada | Revanesse Shape + with Lidocaine, Juvederm Voluma with Lidocaine. | Prollenium Medical Technologies Inc. | Volume Deficit in the Mid-face | 08/23 | 08/23 | | |
| Not yet recruiting | N/A | 16 | US | KeraStat cream, M-PART Assessments via MyCap, Clinical Assessments, Feedback phone interview | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Radiation Dermatitis | 08/26 | 08/26 | | |
| Active, not recruiting | N/A | 5000 | RoW | Edoxaban | Daiichi Sankyo, Inc., Daiichi Sankyo (China) Holdings Co., Ltd. | Non-valvular Atrial Fibrillation | 10/24 | 10/24 | | |
ROCK-RT, NCT05169177: Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy |
|
|
| Recruiting | N/A | 50 | RoW | | University of Sydney, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia, Princess Alexandra Hospital, Brisbane, Australia | Liver Neoplasm | 10/24 | 10/26 | | |
NCT01336790: International Lymphatic Disease and Lymphedema Registry |
|
|
| Recruiting | N/A | 5000 | US | | Stanford University, Lymphatic Education & Research Network | Lymphedema | 12/24 | 12/25 | | |
NCT05531357: Physiologic Mechanisms Underlying Ovarian Follicular Waves During the Menstrual Cycle |
|
|
| Completed | N/A | 50 | Canada | Transvaginal ultrasound scans, Finger-prick blood sampling for dried blood spots, Urine sampling, Venipunctures | University of Saskatchewan, Ansh Labs | Reproductive Issues | 03/24 | 03/24 | | |
| Recruiting | N/A | 200 | US | Education and counseling, Education | Georgetown University | Breast Cancer | 12/24 | 12/25 | | |
NCT05689190: Non-invasive Flow Measurements in Patients With Lower Extremity Arterial Disease (LEAD) |
|
|
| Recruiting | N/A | 30 | Europe | | Philips Clinical & Medical Affairs Global, Leiden University Medical Center | Lower Extremity Arterial Disease | 12/24 | 12/24 | | |
NCT05862467: A Pilot Participatory Program Evaluation of a Virtual Trauma Support Program for Autistic Adults |
|
|
| Recruiting | N/A | 30 | US | Written Exposure Therapy (WET) via telehealth | University of Wyoming | Autism, Trauma, Posttraumatic Stress Disorder, Posttraumatic Stress Symptom | 05/25 | 05/25 | | |
NCT04635111: A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment |
|
|
| Recruiting | N/A | 30 | US | TURALIO™ | Daiichi Sankyo, Inc. | Hepatotoxicity, Tenosynovial Giant Cell Tumor | 06/25 | 03/36 | | |
| Recruiting | N/A | 198 | US | Dietary Intervention Classes | University of South Carolina | Diabetes Mellitus, Type 2, Obesity | 12/25 | 03/26 | | |
MILOS, NCT04579367: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia |
|
|
| Recruiting | N/A | 5000 | Europe | Bempedoic acid and/or its fixed-dose combination with ezetimibe | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Hypercholesterolemia, Mixed Dyslipidemia | 09/25 | 09/25 | | |
NCT06054412: An Adjunctive Neurofeedback Training Program to Enhance Wellness Among Trauma-Exposed Postpartum Mothers |
|
|
| Recruiting | N/A | 20 | US | Neuroptimal (Zengar, Inc.) Neurofeedback | Wayne State University | Well-Being, Psychological, Dissociation, Maternal Care Patterns, Maternal Behavior, Maternal Distress, Mood Disturbance, Emotional Regulation, Post Traumatic Stress Disorder | 09/25 | 03/26 | | |
| Active, not recruiting | N/A | 7 | US | Actual device PFO closure, GORE® CARDIOFORM Septal Occluder, Thienopyridine (clopidogrel or prasugrel), Plavix, Effient, Sham device PFO closure | W.L.Gore & Associates | Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale | 12/25 | 08/26 | | |
SILVERCARE_AF, NCT05804747: A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation |
|
|
| Recruiting | N/A | 1100 | RoW | Edoxaban | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Atrial Fibrillation | 12/25 | 12/25 | | |
LEARN, NCT05184790: Learning Environment for Artificial Intelligence in Radiotherapy New Technology |
|
|
| Not yet recruiting | N/A | 300 | RoW | | University of Sydney, Princess Alexandra Hospital, Brisbane, Australia, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia | Arrhythmias, Cardiac, Breast Cancer, Prostatic Cancer, Brain Cancer, Kidney Cancer, Head and Neck Cancer, Liver Cancer, Pancreatic Cancer, Spinal Neoplasm | 01/26 | 01/26 | | |
NCT05022862: Economic Incentives and vDOT for Latent Tuberculosis Infection |
|
|
| Recruiting | N/A | 399 | US | Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Latent Tuberculosis | 04/26 | 10/26 | | |
NCT05993234: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) |
|
|
| Recruiting | N/A | 257 | Europe | Trastuzumab deruxtecan, T-DXd, ENHERTU® | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | 12/26 | 09/27 | | |
| Recruiting | N/A | 1350 | Europe | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer | 06/27 | 09/28 | | |
NCT05636397: Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC |
|
|
| Recruiting | N/A | 60 | Canada | L-Citrulline | The Hospital for Sick Children | BPD - Bronchopulmonary Dysplasia, Pulmonary Hypertension, NEC | 12/27 | 03/28 | | |
NCT05181163: Biofilm Formation and Antibiotic Sensitivity Patterns |
|
|
| Not yet recruiting | N/A | 100 | NA | swab | Sohag University | Orthopedic Surgery | 07/22 | 01/23 | | |
| Sexton, Wade |
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer |
|
|
| Active, not recruiting | 2/3 | 190 | US | N-803 and BCG, N-803 | ImmunityBio, Inc. | Bladder Cancer | 04/25 | 10/28 | | |
|
|
|
|
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer |
|
|
| Recruiting | 1/2 | 596 | US | BCG+N-803, BCG | ImmunityBio, Inc. | Non-muscle Invasive Bladder Cancer | 12/28 | 12/38 | | |
NCT06253845: Study of CG0070 After Transurethral Resection in Patients With IR NMIBC |
|
|
| Recruiting | 1 | 20 | US | CG0070 | H. Lee Moffitt Cancer Center and Research Institute | Non-muscle Invasive Bladder Cancer | 02/27 | 02/27 | | |
NCT05768347: Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC |
|
|
| Recruiting | 1 | 12 | US | Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL) | H. Lee Moffitt Cancer Center and Research Institute, United States Department of Defense | Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma | 11/24 | 11/25 | | |
| Active, not recruiting | 1 | 21 | US | CG0070, Nivolumab | H. Lee Moffitt Cancer Center and Research Institute, CG Oncology, Inc., Richard M. Shulze Family Foundation | Muscle-Invasive Bladder Carcinoma, Bladder Cancer | 03/25 | 03/25 | | |
| Gaballa, Sameh |
NCT04212013: A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma |
|
|
| Active, not recruiting | 3 | 23 | US | Ibrutinib, Rituximab, Placebo | Memorial Sloan Kettering Cancer Center, Pharmacyclics LLC. | Marginal Zone Lymphoma | 06/24 | 03/27 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
NCT06350318: Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas |
|
|
| Recruiting | 2 | 43 | US | Zanubrutinib, Brukinsa, Rituximab, Rituxin | H. Lee Moffitt Cancer Center and Research Institute, BeiGene, Ltd. | Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma | 03/29 | 03/29 | | |
NCT04548648: A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas |
|
|
| Recruiting | 2 | 16 | US | Acalabrutinib, ACP-196, CALQUENCE, Isavuconazole, Cresemba | UNC Lineberger Comprehensive Cancer Center, AstraZeneca | Central Nervous System Lymphoma | 02/28 | 02/33 | | |
| Recruiting | 1 | 20 | US | Mogamulizumab-Kpkc, POTELIGEO, Phototherapy, nb-UVB | H. Lee Moffitt Cancer Center and Research Institute, Kyowa Hakko Kirin Pharma, Inc. | Mycosis Fungoides | 09/26 | 09/29 | | |
NCT05065866: Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy |
|
|
| Active, not recruiting | 1 | 14 | US | BMS-986345, Oral Azacitidine, Duvelisib, Copiktra | H. Lee Moffitt Cancer Center and Research Institute, Secura Bio, Inc. | Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia | 03/24 | 03/25 | | |
NCT05581030: CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) |
|
|
| Recruiting | 1 | 20 | US | Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Asparlas, CalPeg, Rituximab, Rituxan | H. Lee Moffitt Cancer Center and Research Institute, Servier | Acute Lymphoblastic Leukemia | 05/25 | 05/27 | | |
| Shah, Bijal |
NCT03575325: Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia |
|
|
| Completed | 2 | 11 | US | CPX-351, Vyxeos, cytarabine:daunorubicin | H. Lee Moffitt Cancer Center and Research Institute, Jazz Pharmaceuticals | Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia | 06/21 | 09/23 | | |
NCT06144606: Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) |
|
|
| Recruiting | 2 | 60 | US | Tecartus, Brexucabtagene autoleucel, KTE-X19 | H. Lee Moffitt Cancer Center and Research Institute, Kite, A Gilead Company | B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia | 11/28 | 11/28 | | |
NCT04745559: Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy |
|
|
| Recruiting | 2 | 26 | US | Pneumococcal conjugate vaccine (PCV13), Prevnar 13, CD19 targeted CAR T Cell Therapy | H. Lee Moffitt Cancer Center and Research Institute | Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), High-grade B-cell Lymphoma (HGBCL), Follicular Lymphoma | 08/24 | 05/25 | | |
NCT05757219: Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy |
|
|
| Recruiting | 2 | 27 | US | Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy, YESCARTA, Axi-cel | H. Lee Moffitt Cancer Center and Research Institute, Incyte Corporation | Diffuse Large B Cell Lymphoma | 10/24 | 11/26 | | |
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) |
|
|
| Active, not recruiting | 1/2 | 153 | Europe, US | AUTO1, Obecabtagene autoleucel (obe-cel) | Autolus Limited | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 05/25 | 05/25 | | |
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL |
|
|
| Recruiting | 1 | 129 | US, RoW | Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine | Imugene Limited | Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia | 06/25 | 06/27 | | |
| Recruiting | 1 | 20 | US | Mogamulizumab-Kpkc, POTELIGEO, Phototherapy, nb-UVB | H. Lee Moffitt Cancer Center and Research Institute, Kyowa Hakko Kirin Pharma, Inc. | Mycosis Fungoides | 09/26 | 09/29 | | |
NCT05065866: Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy |
|
|
| Active, not recruiting | 1 | 14 | US | BMS-986345, Oral Azacitidine, Duvelisib, Copiktra | H. Lee Moffitt Cancer Center and Research Institute, Secura Bio, Inc. | Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma, Lymphocytic Leukemia | 03/24 | 03/25 | | |
| Active, not recruiting | 1 | 22 | US | XmAb18968 - Dose level -1, XmAb18968 - Dose level 0 (starting dose), XmAb18968 - Dose level 1, XmAb18968 - Dose level 2, XmAb18968 - Dose level 3 | Ehab L Atallah | Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia, T Cell Lymphoblastic Lymphoma | 04/24 | 04/25 | | |
NCT05694364: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies |
|
|
| Recruiting | 1 | 88 | US | Fludarabine, Fludara, Cyclophosphamide, PRGN-3007 | H. Lee Moffitt Cancer Center and Research Institute, Precigen, Inc | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Triple Negative Breast Cancer Malignancies | 01/26 | 01/26 | | |
